Cargando…
Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder
Brexpiprazole is an atypical antipsychotic that works as a partial agonist at serotonin 5-hydroxytryptamine(1A) and dopamine D(2) receptors and an antagonist at serotonin 5-hydroxytryptamine(2A). It has US Food and Drug Administration approval for monotherapy treatment of schizophrenia and adjunctiv...
Autores principales: | Diefenderfer, Lauren A., Iuppa, Courtney |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
College of Psychiatric & Neurologic Pharmacists
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007711/ https://www.ncbi.nlm.nih.gov/pubmed/29955525 http://dx.doi.org/10.9740/mhc.2017.09.207 |
Ejemplares similares
-
A review of citalopram dose restrictions in the treatment of neuropsychiatric disorders in older adults
por: McCarrell, Jamie L., et al.
Publicado: (2019) -
Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression?
por: Peckham, Alyssa M., et al.
Publicado: (2018) -
Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action
por: Irwin, Madison N., et al.
Publicado: (2021) -
Istradefylline: A novel agent in the treatment of “off” episodes associated with levodopa/carbidopa use in Parkinson disease
por: Cummins, Lauren, et al.
Publicado: (2022) -
Early Australian experience in the maintenance of schizophrenia management with 3-monthly paliperidone palmitate
por: Pai, Nagesh, et al.
Publicado: (2018)